Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Drug Intelligence & Clinical Pharmacy|April 1, 1985
Exercise and beta-blocking agentsL K Golightly, E W SutherlandMedical Toxicology and Adverse Drug Experience|March 1, 1988
Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I)L K Golightly, S S Smolinske, M L Bennett, et al.Pharmacotherapy|May 1, 1982
Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effectsL K GolightlyAmerican Journal of Hospital Pharmacy|February 1, 1988
Documenting the activity and effectiveness of a regional drug information centerL K Golightly, A G Davis, W J Budwitz, et al.Drug Intelligence & Clinical Pharmacy|December 1, 1984
Chelation therapy of atherosclerosisK L Rathmann, L K GolightlyProceedings of the National Academy of Sciences of the United States of America|May 1, 1975
Action of feedback regulator on adenylate cyclaseR J Ho, E W SutherlandHospital Pharmacy|August 1, 1993
Pharmacist monitoring of drug therapy in patients with abnormal serum creatinine levelsL K Golightly, C L O'Fallon, W D Moran, et al.Clinical Chemistry|September 1, 1975
Concepts for the rational selection of assays to be used in monitoring therapeutic drugsM Werner, E W Sutherland, F P AbramsonProceedings of the National Academy of Sciences of the United States of America|January 1, 1972
Synthesis and secretion of gammaglobulin by lymph node cells: the acquisition of carbohydrate residues of immunoglobulin in relation to interchain disulfide bond formation (heavy and light chains-murine myeloma-mannose-glucosamine-galactose)E W Sutherland, D H Zimmerman, M KernPageof 3